Takeda Reports Long-Term Safety and Efficacy Results of its Dengue Vaccine Candidate

 Takeda Reports Long-Term Safety and Efficacy Results of its Dengue Vaccine Candidate

Shots:

  • The P-III TIDES study involves assessing two doses of TAK-003 (0.5mL, SC on day 1 & 90) vs PBO to prevent laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in 20,000+ children and adolescents
  • Results: @36mos. after the second dose, 62.0% VE against VCD; 65.0% VE in seropositive; 54.3% VE in seronegative individuals. TAK-003 also demonstrated 83.6% VE against hospitalized dengue, with 86.0% VE in seropositive & 77.1% VE in seronegative individuals
  • The regulatory filing in the EU and dengue-endemic countries is under progress while the company plan to regulatory application in the US in late 2021

Click here to­ read full press release/ article | Ref: Takeda | Image: GENEOnline

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post